Finerenone (Kerendia®) for the Treatment of Heart Failure (HF) in Adults
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for finerenone (Kerendia) as an adjunct to standard of care therapy in adults for the treatment of heart failure (HF) with mildly reduced or preserved ejection fraction (Left Ventricular Ejection Fraction [LVEF] greater than or equal to 40%) to reduce the risk of cardiovascular death, hospitalization for HF, and urgent HF visits.